SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

ORTIZ LOBO, Alberto  and  IBANEZ ROJO, Vicente. Iatrogenia y prevención cuaternaria en salud mental. Rev. Esp. Salud Publica [online]. 2011, vol.85, n.6, pp. 513-525. ISSN 1135-5727.  http://dx.doi.org/10.1590/S1135-57272011000600002.

    1. Jamoulle M. Information et informatisation en mdecine gnrale. Dans: Les informa-g-iciens. Brussels: Presses Universitaires de Namur; 1986: 193-209. [ Links ]

    2. Kuehlein T, Sghedoni D, Visentin G, Grvas J, Jamoule M. Quaternary prevention: a task of the general practitioner. Primary Care. 2010; 10(18): 350-4. [ Links ]

    3. Steel K, Gertman PM, Crescenzi C, Anderson J. "Iatrogenic illness on a general medical service at a university hospital". N Engl J Med. 1981; 304 (11): 638-42. [ Links ]

    4. Starfield B. Is US Health Really the Best in the World? JAMA. 2000; 284, 4: 483. [ Links ]

    5. Phillips DP, Christenfeld N, Glynn LM. Increase in US medication-error deaths between 1983 and 1993. Lancet. 1998; 351 (9103): 643-644. [ Links ]

    6. Lazarou J, Pomeranz BH, Corey PN. Incidence of Adverse Drug Reactions in Hospitalized Patients. JAMA. 1998; 279(15): 1200-1205. [ Links ]

    7. Landrigan CP et al. Temporal trends in rates of patient harm resulting from medical care. N Engl J Med. 2010; 363: 2124-34. [ Links ]

    8. Gervas J. Cuatro ejemplos de necesidad de prevencin cuaternaria en Espaa. Gac Sanit. 2006; 20(Supl 1): 127-34. [ Links ]

    9. Ortiz Lobo A, Mata Ruiz I. Ya es primavera en salud mental. Sobre la demanda en tiempos de mercado. topos 2004; 2 (1): 15-22. http://www.atopos.es/pdf_03/yaesprimavera.pdf [ Links ]

    10. Health I. In defence of a National Sickness Service. BMJ. 2007; 334:19. [ Links ]

    11. Grvas J, Prez Fernndez M. Uso y abuso del poder mdico para definir enfermedad y factor de riesgo, en relacin con la prevencin cuaternaria. Gac Sanit. 2006; 20(supl3): 66-71. [ Links ]

    12. Verweij M. Medicalization as a moral problema for preventive medicine. Bioethics 1999;13(2):89-113. [ Links ]

    13. Neimeyer R. Searching for the meaning of meaning: Grief therapy and the process of reconstruction. Death Studies. 2000; 24:541-558. [ Links ]

    14. Sijbrandji B, Olff M, Reitsma JB, Carlier IVE, Gersons BPR. Emotional or educational debriefing after psychological trauma: randomised controlled trial. Br J Psychiatry. 2006; 189: 150-155. [ Links ]

    15. Rose SC, Bisson J, Churchill R, Wessely S. Psychological debriefing for preventing post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD000560. DOI: 10.1002/14651858.CD000560. [ Links ]

    16. Warner R. Problems with early and very early intervention in psychosis. Br J Psychiatry. 2005;187(suppl48 ):104-107. [ Links ]

    17. Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database of Systematic Reviews 2011, Issue 6. Art. No.: CD004718. DOI: 10.1002/14651858.CD004718.pub3. [ Links ]

    18. Corcoran CH, Malaspina D, Hercher L. Prodromal interventions for schizophrenia vulnerability: the risks of being "at risk". Schizophr Res. 2005; 73(2-3):173-184. [ Links ]

    19. Weiser M. Early Intervention for Schizophrenia: The Risk-Benefit Ratio of Antipsychotic Treatment in the Prodromal Phase. Am J Psychiatry. 2011;168:761-763. [ Links ]

    20. Frances A. DSM_V in distress. Disponible en: http://www.psychologytoday.com/blog/dsm5-in-distress. [ Links ]

    21. Healy D. The Latest Mania: Selling Bipolar Disorder. PLoS Med 2006; 3(4): e185. doi:10.1371/journal.pmed.0030185 [ Links ]

    22. Read J, van Os J, Morrison AP, Ross CA. Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implication. Acta Psychiatr Scand. 2005: 112: 330-350. [ Links ]

    23. Bentall RP. The environment and psychosis: rethinking the evidence. In Trauma and psychosis: new directions for theory and therapy. Warren Larkin and Anthony P. Morrison Eds. Routledge: New York; 2006. [ Links ]

    24. Boisvert CM, Faust D. Iatrogenic symptoms in psychotherapy: A theoretical exploration of the potential impact of labels, language, and belief systems. Am J Psychother 2002; 56: 244-260. [ Links ]

    25. Crown S. Contraindications and dangers of psychotherapy. Br J Psychiatry 1983; 143:436-441. [ Links ]

    26. Kuehlein T, Sghedoni D, Visentin G, Grvas J, Jamoule M. Quaternary prevention: a task of the general practitioner. Primary Care 2010; 10(18): 350-4. [ Links ]

    27. Salzburg Global Seminar. Salzburg statement on shared decision making. BMJ 2011; 342: d1745. [ Links ]

    28. Angermeyer MC, Holzinger A, Carta MG, Schomerus G. Biogenetic explanations and public acceptance of mental illness: systematic review of population studies. Br J Psychiatry 2011; 199: 367-372. [ Links ]

    29. Read J, Haslam N, Sayce L. Davies E. Prejudice and schizophrenia: a review of the 'mental illness is an illness like any other' approach. Acta Psychiatr Scand 2006; 114: 303-318. [ Links ]

    30. Mitsumoto S. Renaming schizophrenia: a Japanese perspective. World Psychiatry 2006; 5: 53-55. [ Links ]

    31. Romme M, Morris M. The harmful concept of Schizophrenia. Mental Health Nursing. 2007; March: 7-11. [ Links ]

    32. CASL: Campaign to Abolish the Schizophrenia Label (2010). Disponible en http://www.caslcampaign.com/index.php y en http://www.facebook.com/group.php?gid=63200257336&v=info&ref=mf [ Links ]

    33. CAPSID: Campaign to Abolish Psychiatric Diagnostic Systems such as ICD and DSM (2011). Disponible en http://www.criticalpsychiatry.net/?p=527 [ Links ]

    34. Timimi S. Campaign to Abolish Psychiatric Diagnostic Systems such as ICD and DSM (March 2011). Disponible en: http://www.criticalpsychiatry.net/wp-content/uploads/2011/05/CAPSID11.pdf [ Links ]

    35. Caplan PJ, Cosgrove L. Bias in Psychiatric Diagnosis. Jason Aronson: New York; 2004. [ Links ]

    36. CIE-10. International statistical classification of diseases and related health problems. Tenth Revision. 2nd ed. WHO Library: Geneva; 2004. [ Links ]

    37. Ortiz Lobo A, Gonzlez Gonzlez R, Rodrguez Salvans F. La derivacin a salud mental de pacientes sin un trastorno psquico diagnosticable. Aten Primaria 2006; 38(10):563-9. [ Links ]

    38. Bootzin RR, Bailey ET. Understanding placebo, nocebo and iatrogenic treatment effects. J Clin Psychology 2005;61:871-880. [ Links ]

    39. Moncrieff J, Cohen D. Rethinking models of psychotropic drug action. Psychother Psychosom 2005; 74:145-153. [ Links ]

    40. Healy D. The creation of psychopharmacology. Cambridge MA: Harvard University Press; 2002. [ Links ]

    41. Bola JR, Mosher LR. Predicting Drug-Free Treatment Response in Acute Psychosis from the Soteria Project. Schizophr Bull 2002; 28(4):559-575. [ Links ]

    42. Seikkula J, Aaltonen J Alakare B, Haarakangas K, Keranen J, Lehtinen K. Five-year experience of first-episode nonaffective pychosis in open-dialogue approach: Treatment principles, follow-up outcomes, and two case studies. Psychother Res 2006; 16(2): 214-228. [ Links ]

    43. Forrest DV, Fahn S. Tardive dysphrenia and subjective akathisia. J Clin Psychiatry 1979; 40 (4): 206. [ Links ]

    44. Frota LH. Partial Agonists in the Schizophrenia Armamentarium. Tardive Dysphrenia: The newest challenge to the last generation atypical antipsychotics drugs? J Bras Psiquiatr 2003; 52 (Suppl 1): 14-24. [ Links ]

    45. Fernandez HH. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord 2005; 20(1): 104-5. [ Links ]

    46. Margolese HC. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2002; 22(4): 347-52. [ Links ]

    47. Chouinard G, Chouinard VA. Atypical Antipsychotics: CATIE Study, Drug-Induced Movement Disorder and Resulting Iatrogenic Psychiatric-Like Symptoms, Supersensitivity Rebound Psychosis and Withdrawal Discontinuation Syndromes. Psychother Psychosom 2008;77:69-77. [ Links ]

    48. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 2006;114:3-13. [ Links ]

    49. Whitaker R. Anatomy of an epidemic. Magic bullets, psychiatric drugs and the astonishing rise of mental illness in America. Crown Publishers: New York; 2010. [ Links ]

    50. Gardos G, Cole J. Maintenance Antipsychotic Therapy. Is the Cure Worse than the Disease? Am J Psychiatry 1977; 132: 32-6. [ Links ]

    51. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011; 68(2):128-37. [ Links ]

    52. Moncrieff J. Questioning the 'neuroprotective' hypothesis: does drug treatment prevent brain damage in early psychosis or schizophrenia? Br J Psychiatry 2011; 198: 85-87. [ Links ]

    53. Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia. A naturalistic study. Eur Arch Psychiatry Clin Neurosci 2007; 257(3): 169-72. [ Links ]

    54. Gur R. A follow-up of magnetic resonance imaging study of schizophrenia. Arch Gen Psychiatry 1998; 55: 145-151. [ Links ]

    55. Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. J Nerv Ment Dis 2007; 195(5): 406-14. [ Links ]

    56. Leff, J. The International Pilot Study of Schizophrenia. Psychol Med 1992; 22:131-145. [ Links ]

    57. Vigen CLP, Mack WJ, Keefe RSE, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS. Cognitive Effects of Atypical Antipsychotic Medications in Patients with Alzheimer's Disease: Outcomes From CATIE-AD. Am J Psychiatry 2011; 168: 831-839. [ Links ]

    58. Devanand DP, Schultz SK. Consequences of Antipsychotic Medications for the Dementia Patient. Am J Psychiatry 2011; 168: 767-769. [ Links ]

    59. Corts Morales, B. Sndrome metablico y antipsicticos de segunda generacin. Rev Asoc Esp Neuropsiquiatr 2011; 31 (110): 303-320. [ Links ]

    60. Weinmann S, Aderhold V. Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses. Psychosis 2010; 2:50-69. [ Links ]

    61. Calton T, Spandler H. Minimal-medication approaches to treating schizophrenia. Advances of Psychiatric Treatment 2009; 15:209-217. [ Links ]

    62. Kendall T. The rise and fall of the atypical antipsychotics. Br J Psychiatry 2011; 199: 266-268. [ Links ]

    63. Jonathan S. Comer JS, Mojtabai R, Olfson M. National Trends in the Antipsychotic Treatment of Psychiatric Outpatients with Anxiety Disorders. Am J Psychiatry 2011; 168: 1057-1065. [ Links ]

    64. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2005; 18 (3): 249-255. [ Links ]

    65. Barker M. Cognitive effects of long-term benzodiazepine use. CNS Drugs 2004; 18:37-48. [ Links ]

    66. Fava, G. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry 2003; 64:123-33. [ Links ]

    67. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358(3): 252-260. [ Links ]

    68. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5(2): e45. [ Links ]

    69. Pigott HE, Leventhal AM, Alter GS, Boren JJ. Efficacy and Effectiveness of Antidepressants: Current Status of Research. Psychother Psychosom 2010; 79: 267-27. [ Links ]

    70. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J. Antidepressant Drug Effects and Depression Severity. A Patient-Level Meta-analysis. JAMA 2010; 303(1):47-53. [ Links ]

    71. Barbui C, Cipriani A, Patel V, Ayuso-Mateos JL, van Ommeren M.Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. Br J Psychiatry 2011; 198(1):11-6. [ Links ]

    72. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J, Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011; 343:d4551 [ Links ]

    73. Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonki AL. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004; 328: 879-8. [ Links ]

    74. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356(17): 1711-22. [ Links ]

    75. Ghaemi SN. Treatment of Rapid-Cycling Bipolar Disorder: Are Antidepressants Mood Destabilizers? Am J Psychiatry 2008; 165: 300-302. [ Links ]

    76. Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 2008; 118(5): 347-356. [ Links ]

    77. Frighi V, Stephenson MT, Morovat A, Jolley LE, Trivella M, Dudley CA, Anand E, White SJ, Hammond CV, Rena A. Hockney RA, Barrow B, Shakir R, Goodwin GM. Safety of antipsychotics in people with intellectual disability. Br J Psychiatry 2011; 199:289-29. [ Links ]

    78. Timimi S, Leo J, eds. Rethinking ADHD: from brain to culture. Palgrave: Macmillan; 2009. [ Links ]

    79. Cosgrove L, Bursztajn HL, Krimsky S, Anaya M, Walker J. Conflicts of Interest and Disclosure in the American Psychiatric Association's Clinical Practice Guidelines. Psychother Psychosom 2009; 78:228-232. [ Links ]

    80. Mohr. Negative outcome in psychotherapy: A critical review. Clinical Psychology: Science and Practice 1995; 2: 1-27. [ Links ]

    81. Moos R. Iatrogenic effects of psychosocial interventions for substance use disorders: prevalence, predictors, prevention. Addiction 2005; 5: 595. [ Links ]

    82. Lilienfeld, S. O. Psychological treatments that cause harm. Perspectives on Psychological Science 2007; 2: 53-70. [ Links ]

    83. Crown S. Contraindications and dangers of psychotherapy. Br J Psychiatry 1983; 143: 436-441. [ Links ]

    84. Perdign A. Prevencin y iatrogenia en rehabilitacin psicosocial. Boletn de la AMSM 2010 (primavera):8-13. [ Links ]

    85. Mary Nettle. Mental Health Visions. Disponible en http://www.youtube.com/watch?v=_if4Wyh_CTg [ Links ]

    86. Bassman, R. Agents, not objects: our fight to be. J Clin Psychology 2000; 56: 1395-1411. [ Links ]

    87. Zygmond T. Pressures to adhere to treatment: observations on "leverage" in english mental health care. Br J Psychiatry 2011; 199: 90-91. [ Links ]

    88. Alonso C, Escudero A. Algunas reflexiones sobre la demanda social y la rehabilitacin de pacientes crnicos. Rehabilitar o encontrar un sitio al crnico? Boletn de la AMSM 2004 (octubre):8-12. [ Links ]

    89. ENUSP. Harassment and discrimination faced by people with psycho-social disability in health services. A European survey. Disponible en http://www.enusp.org/documents/harassment/overview.htm [ Links ]

    90. Rose, D. Users' Voices: The perspective of mental health service users on community and hospital care. The Sainsbury Centre for Mental Health: London; 2001. [ Links ]

    91. Muiz E. Enrolamiento clnico, desenrolamiento social. Boletn de la AMSM 2007; otoo:10-15. [ Links ]

    92. Hasson-Ohanon I, Kravetz, S, Roe D, David A, Weiser M. Insight into psychosis and quality of life. Compr Psychiatry 2006; 47: 265-269. [ Links ]

    93. Wykes T. Social Functioning in Residential and Institutional Settings. En KT Mueser and N Tarrier (eds): Handbook of Social Functioning in Schizophrenia. Allyn & Bacon: Mass; 1998. [ Links ]

    94. Chilvers R, Macdonald G, Hayes A. Residencias de apoyo para las personas con trastornos mentales graves. (Revisin Cochrane traducida). En La biblioteca Cochrane Plus, No3 Oxford. Update Software Ltd. 2008. [ Links ]

    95. Frances A, Clarkin JF. No treatment as the prescription of choice. Arch Gen Psychiatry 1981; 38: 542-5. [ Links ]

    96. Hernndez Monsalve M. Dilemas en psiquiatra: entre el consumismo, la eficiencia y la equidad. En: Neoliberalismo versus democracia. VV.AA.: Madrid; 1998. [ Links ]

    97. Endicott NA, Endicott J. Improvement in untreated psychiatric patients. Arch Gen Psychiatry 1963; 9:575-585. [ Links ]

    98. Spielmans GI, Parry PI. From Evidence-based Medicine to Marketing-based Medicine: Evidence from Internal Industry Documents. Bioethical Inquiry 2010; 7(1):13-29. [ Links ]

    99. Convencin de las Naciones Unidas de los Derechos de las Personas con Discapacidad. Disponible en http://www.un.org/spanish/disabilities/convention/qanda.html [ Links ]